Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
How to see the Ursids, the final meteor shower of 2025 - 2Poland identifies two Ukrainian suspects in railway sabotage blast
- 3Egypt seeks to calm tourist fears over fallout of Iran war
- 4A soft launch, an unfollow and a lot of questions: Breaking down the 'Summer House' romance blowing up group chats
- 5The most effective method to Pick the Best Material Organization: Insider Tips
- Netflix’s Price Hikes Just Got Rejected by an Italian Court. Here’s Why It Matters Everywhere
- Find the Keys to Fruitful Venture The board: Conveying Results on Time
- Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- Surprising links between autism, Alzheimer’s could change how we treat both
- Egypt's cafés and shops forced to close early due to Iran war
- Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
- Delta flight bound for Atlanta makes emergency landing after engine issue
- Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
